

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

**PRECLINICAL AND PHASE I CLINICAL DATA OF MT200605
ACCEPTED FOR ORAL PRESENTATION AT THE 18TH WORLD
STROKE CONGRESS 2026**

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the preclinical and Phase I clinical data of the Group’s independently developed injectable neuroprotective drug candidate MT200605 for the treatment of acute ischemic stroke (AIS), has been accepted for an oral presentation at the 18th World Stroke Congress 2026 (“**WSC 2026**”).

About WSC

The WSC is organized by the World Stroke Organization (“**WSO**”), the only international organization dedicated exclusively to stroke worldwide. It is one of the major international academic platforms in the field of stroke, providing a forum for experts and researchers worldwide to exchange views on cutting-edge research, clinical trials and innovative therapeutic strategies.

Title: MT200605: A Novel Bifunctional Neuroprotectant for Ischemic Stroke

Session: FC01 – Basic Science, Translational Research & Biomarkers

Presentation Type: Oral Presentation

Congress: WSC 2026 (Seoul, Korea | October 21-23, 2026)

Date & Time: Wednesday, October 21, 2026, 08:00-09:30 a.m., KST

Room: Conference Room 201, COEX, Seoul, Korea

The Phase I clinical studies of MT200605, conducted in both the PRC and the United States, were designed to evaluate the safety, tolerability and pharmacokinetics of MT200605 in healthy subjects.

About MT200605

MT200605 is an injectable neuroprotective agent with a dual synergistic mechanism of action. To the knowledge of the Company, MT200605 is the only neuroprotective agent globally that can penetrate the blood-brain barrier (“**BBB**”) and act on the BDNF/TrkB pathway that has entered the clinical development stage. MT200605 also exerts antioxidative effects and alleviates microcirculatory obstruction caused by calcium ion-induced vascular smooth muscle contraction, thereby targeting multiple stages of the ischemic cascade following AIS while supporting neural repair and remodeling.

Echoing the acceptance of its preclinical and Phase I clinical data for oral presentation at WSC 2026, the Phase II clinical trial of MT200605 for AIS has reached its primary endpoint with statistically significant and clinically meaningful outcomes. Detailed clinical data will be presented at international academic conferences and published in academic journals in the future. Based on the currently available Phase II clinical results, MT200605 demonstrated significant and robust efficacy in patients with AIS, with a favorable safety and tolerability profile.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi’an, Shaanxi, the PRC, 10 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.